With partner Eli Lilly’s help, the radiopharmaceutical drugmaker priced one of the sector’s largest new stock offerings in the last two years.
The hefty funding will fuel Phase 2 testing of a drug with a similar mechanism to Amgen’s closely watched obesity drug, as ...
The financing, which will back a novel type of cancer drug, is the largest of a series of startup fundings announced at the ...
The startup is developing a medicine that can very specifically degrade cancerous forms of EGFR, the target of an array of ...
Backed by more than a dozen prominent investors, the startup is advancing into human testing a drug it believes capable of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback